We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
West Pharmaceutical (WST) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Analysts on Wall Street project that West Pharmaceutical Services (WST - Free Report) will announce quarterly earnings of $2.18 per share in its forthcoming report, representing an increase of 11.2% year over year. Revenues are projected to reach $825.93 million, increasing 2.7% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific West Pharmaceutical metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Net Sales- West Vantage' stands at $144.68 million. The estimate indicates a year-over-year change of -7.9%.
It is projected by analysts that the 'Net Sales- Proprietary Products' will reach $682.68 million. The estimate indicates a change of +5.4% from the prior-year quarter.
The consensus among analysts is that 'Gross Profit- Proprietary Products' will reach $297.25 million. The estimate compares to the year-ago value of $264.00 million.
Analysts expect 'Gross Profit- West Vantage' to come in at $23.80 million. The estimate is in contrast to the year-ago figure of $30.30 million.
Over the past month, shares of West Pharmaceutical have returned +5.8% versus the Zacks S&P 500 composite's -0.2% change. Currently, WST carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
West Pharmaceutical (WST) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Analysts on Wall Street project that West Pharmaceutical Services (WST - Free Report) will announce quarterly earnings of $2.18 per share in its forthcoming report, representing an increase of 11.2% year over year. Revenues are projected to reach $825.93 million, increasing 2.7% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific West Pharmaceutical metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Net Sales- West Vantage' stands at $144.68 million. The estimate indicates a year-over-year change of -7.9%.
It is projected by analysts that the 'Net Sales- Proprietary Products' will reach $682.68 million. The estimate indicates a change of +5.4% from the prior-year quarter.
The consensus among analysts is that 'Gross Profit- Proprietary Products' will reach $297.25 million. The estimate compares to the year-ago value of $264.00 million.
Analysts expect 'Gross Profit- West Vantage' to come in at $23.80 million. The estimate is in contrast to the year-ago figure of $30.30 million.
View all Key Company Metrics for West Pharmaceutical here>>>Over the past month, shares of West Pharmaceutical have returned +5.8% versus the Zacks S&P 500 composite's -0.2% change. Currently, WST carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .